A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes
- 30 November 2008
- journal article
- research article
- Published by Elsevier BV in Clinical Therapeutics
- Vol. 30 (11), 1976-1987
- https://doi.org/10.1016/j.clinthera.2008.11.001
Abstract
No abstract availableKeywords
Funding Information
- Novo Nordisk
This publication has 22 references indexed in Scilit:
- Long‐term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat‐to‐target basal–bolus regimen with insulin aspart at meals: a 2‐year, randomized, controlled trialDiabetic Medicine, 2008
- A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetesDiabetologia, 2008
- Refining basal insulin therapy: what have we learned in the age of analogues?Diabetes/Metabolism Research and Reviews, 2007
- Towards peakless, reproducible and long‐acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studiesDiabetes, Obesity and Metabolism, 2007
- 3-Month Results from Denmark within the Globally Prospective and Observational Study to Evaluate Insulin Detemir Treatment in Type 1 and Type 2 Diabetes: The PREDICTIVE StudyThe Review of Diabetic Studies, 2007
- Albumin‐bound basal insulin analogues (insulin detemir and NN344): comparable time‐action profiles but less variability than insulin glargine in type 2 diabetesDiabetes, Obesity and Metabolism, 2006
- Does insulin detemir have a role in reducing risk of insulin‐associated weight gain?Diabetes, Obesity and Metabolism, 2006
- A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naïve People With Type 2 DiabetesDiabetes Care, 2006
- Insulin detemir used in basal‐bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulinDiabetes, Obesity and Metabolism, 2004
- When oral agents fail: practical barriers to starting insulinInternational Journal of Obesity, 2002